CliffBio
small molecule

PROMACTA

ELTROMBOPAG OLAMINE

Loss of exclusivityJanuary 2026latest FDA-listed patent expiry
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand namePROMACTA
Active ingredientELTROMBOPAG OLAMINE
StrengthEQ 100MG ACID **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2012
Marketing statusDISCN

Listed patents

PatentExpiresType
7547719*PEDJanuary 2026—
7547719July 2025substance, product

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

PROMACTA patent cliff — loss of exclusivity January 2026 | CliffBio